Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.

scientific article published on 3 January 2012

Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/10428194.2011.631159
P932PMC publication ID4225703
P698PubMed publication ID21988645

P50authorYago NietoQ85372325
Muzaffar QazilbashQ87088891
Elizabeth J ShpallQ87373605
Stefan O CiureaQ87848230
Richard E ChamplinQ89187648
Roland L BassettQ91497807
Partow KebriaeiQ104745054
Gabriela RondonQ114427983
Rima M SalibaQ114428014
Laura WorthQ114428072
John McMannisQ116793080
Demetrios PetropoulosQ117233466
Roy B. JonesQ122694370
Chitra HosingQ37840480
Nelson HamerschlakQ42383096
Marcelo A. Fernández-ViñaQ59750308
Amado Karduss-UruetaQ73549352
P2093author name stringManish Sharma
Marcos de Lima
Daniel R Couriel
Ka Wah Chan
P2860cites workOutcomes among 562 recipients of placental-blood transplants from unrelated donorsQ77598678
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignanciesQ80066587
Nonparametric Estimation from Incomplete ObservationsQ25938997
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationQ31828080
Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitutionQ33819877
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.Q33841389
Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cellsQ33858964
Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trialQ33861192
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donorsQ33951486
Donor-derived second hematologic malignancies after cord blood transplantationQ33952705
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survivalQ34144410
Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantationQ34510349
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantationQ35073502
Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewingQ36447936
Chronic graft-versus-host disease and other late complications of bone marrow transplantation.Q37295704
Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipientsQ39258753
1994 Consensus Conference on Acute GVHD GradingQ39513397
The Analysis of Failure Times in the Presence of Competing RisksQ41031423
Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantationQ42154867
Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia.Q43278450
Unrelated umbilical cord blood transplantation in adult patientsQ44694397
High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalanQ46807795
A Survey of Exact Inference for Contingency TablesQ56432188
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancyQ56777948
Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipientsQ71133353
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseasesQ74106097
P433issue5
P921main subjectthymocyteQ7799635
P304page(s)901-906
P577publication date2012-01-03
P1433published inLeukemia & LymphomaQ6534493
P1476titleFludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant
P478volume53

Reverse relations

cites work (P2860)
Q43156049A combination treatment approach and cord blood stem cell transplant for blastic plasmacytoid dendritic cell neoplasm
Q36905573A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation
Q53315058Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.
Q36622322High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia
Q49218292High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation.
Q85830183Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies
Q44756831Long-term outcome and prognostic factors of unrelated cord blood transplantation in children with haematological malignancies: a retrospective study using the Spanish Working Party for BMT in Children (GETMON) database

Search more.